C. L. Moertel

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.

Perinatal folate levels do not influence tumor latency or multiplicity in a model of NF1 associated plexiform-like neurofibromas

This study investigates whether pregestational folate intake affects tumor latency and multiplicity in a transgenic NF1 mouse model, finding no significant differences in tumor outcomes across folate groups.

CD200 immune checkpoint reversal at the site of tumor vaccine inoculation: A novel approach to glioblastoma immunotherapy

This paper demonstrates that a CD200 peptide inhibitor enhances immune response in glioblastoma by reversing tumor-induced immunosuppression and downregulating PD-1 receptors.